ArticleBMC pulmonary medicine2025
Symptomatic pleural effusion in adult liver transplant candidates: prevalence, disease severity and post-transplant mortality.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSymptomatic pleural effusion in patients with decompensated cirrhosis—often termed hepatic hydrothorax—is thought to reflect advanced disease and may carry poor prognosis. However, its impact on outcomes after liver transplantation remains uncertain.
methodsIn this retrospective cohort study, we evaluated all adult patients who underwent their first liver transplantation at a single tertiary centre between 2015 and 2022. Baseline demographics, clinical characteristics and disease severity scores were extracted from institutional databases. The presence of symptomatic pleural effusion requiring therapeutic intervention was determined from imaging reports and clinical records. Multivariable logistic regression was used to assess associations between pleural effusion and mortality at 30 days, 90 days and overall, adjusting for age, sex, Model for End-Stage Liver Disease (MELD) score and ascites.
resultsOf 459 transplant candidates, 59 (12.8%) had symptomatic pleural effusion. These patients displayed higher MELD scores and a greater prevalence of ascites compared with those without effusion, though age and sex distributions were similar. Unadjusted mortality rates were higher in the effusion group (20.3%, 28.8% and 33.9% at 30 days, 90 days and overall, respectively), but in multivariable analyses pleural effusion was not an independent predictor of mortality at any time point. MELD score showed a borderline association with early mortality.
conclusionsSymptomatic pleural effusion is common among liver transplant candidates and is associated with more advanced liver disease, yet it does not independently increase post-transplant mortality. These findings suggest that pleural effusion should prompt careful optimisation of ascites and early transplant evaluation but need not preclude transplantation. Future studies should explore effusion characteristics and management strategies to better stratify risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.